Introduction
Currently, transplantation of any solid organ incurs a lifelong burden of immunosuppression. In spite of many advances, the basic premises of immunosuppression remain unchanged. As such, substantial renal, metabolic, infectious, and neoplastic complications threaten the recipient's life and well being after transplantation. This concern is heightened when considering pediatric transplant recipients who face the longest lifetimes beyond transplantation [1, 2] . For pediatric liver transplant recipients, the distant posttransplant horizon is just coming into view as the numbers of medium and long-term survivors burgeon [3] . In this article, we will briefly outline outcomes of pediatric liver transplantation and then present emerging data regarding the mortality and morbidity of immunosuppression. We will then review promising strategies to minimize the cumulative burden of immunosuppression.
Current outcomes of pediatric liver transplantation
It is well known that the last decade has witnessed tremendous improvements in short-term liver transplant outcomes. Figure 1 shows declining death rates after deceased donor liver transplantation for all pediatric age groups with the most dramatic decrease in the less than 1 year of age cohort [3] . Medium-term outcomes have recently been reported by The Studies of Pediatric Liver Transplantation (SPLIT) registry [4 ] . For patients transplanted between 1995 and 2005 who were alive with their primary allografts 1 year after transplant and had at least 1 additional year of follow-up, 5-year Kaplan-Meier patient and graft survival was 94.2 and 89.2%, respectively. Figure 2 illustrates the slow but steady patient and allograft attrition over time.
Causes of patient death and graft loss after pediatric liver transplantation
Causes of death and graft loss after pediatric liver transplantation have recently been updated by the SPLIT registry [5] . Of the 2291 children that underwent primary liver transplantation between 1995 and 2006, 274 (12%) died. Assigning the cause of death and consideration of its potential relationship to immunosuppression yielded striking data. Infection contributed directly or indirectly, typically through multisystem organ failure or cardiopulmonary failure, to nearly half of all deaths (125 of 274; 46%). Malignancy accounted for an additional 15 deaths (5.1%). In contrast, rejection contributed directly or indirectly, by necessitating re-transplantation, to only 13 deaths (4.7%). Re-transplantation was required for 236 children (10%). Primary nonfunction and technical complications accounted for the majority of re-transplants (64%) though rejection was responsible for 36 cases (15%). Among patient subgroups, infants were simultaneously at highest risk to develop infections and at lowest risk to experience rejection. The authors concluded that infection, compared with rejection, posed steeply higher risks of both mortality and morbidity.
The landscape of late deaths and graft loss after pediatric liver transplantation has also been recently painted by the SPLIT registry [4 ] . Among the 872 pediatric liver transplant recipients alive at 1 year with their primary graft and with a minimum of an additional 12 months of follow-up, 34 died and an additional 35 lost their grafts. Sepsis/ infection (n ¼ 5), multisystem organ failure (n ¼ 5), and posttransplant lymphoproliferative disorders (PTLD) (n ¼ 4), clear complications of immunosuppression, accounted for 14 out of the 34 deaths (41%). Immunosuppression may have been a contributing factor to an additional seven deaths from malignancy (21%). Chronic rejection accounted for a single recipient death. In contrast, insufficient immunosuppression resulting in chronic rejection (n ¼ 13), acute rejection (n ¼ 4), and 'stopped immunosuppression' (n ¼ 1) were the dominant causes of graft loss, accounting for half of the cases (18 out of 35; 51%).
Immunosuppression withdrawal after pediatric liver transplantation Feng 507 Kaplan-Meier patient and graft survival for recipients who were alive 1 year after transplantation with functioning primary allografts. , patient survival;
, graft survival. Reproduced with permission from [4 ] .
Morbidity of long-term immunosuppression
In assessing the long-term toll exacted by immunosuppression on the well being of pediatric liver transplant recipients, one must look beyond the endpoints of death and graft loss.
Chronic kidney disease
Chronic kidney disease is now well recognized as a major threat to the overall health of liver transplant recipients. Ojo et al. [6] brought the issue sharply into view when they reported that the cumulative incidence of chronic renal failure was 26% for adult liver transplant recipients followed for at least 10 years. For children, available data suggest that though rates of renal failure are low, the prevalence of chronic kidney disease is high [7] [8] [9] [10] [11] . The largest and best study to date has come from Cincinnati Children's Hospital [11] . Glomerular filtration rate (GFR) was measured in all pediatric recipients of primary, solitary liver transplants between July 1986 and November 1999 (n ¼ 117). At a mean follow-up of 7.6 years (range 3-14.6 years), 37 patients (31.6%) had measured GFR less than 70 ml/min per 1.73 m 2 , corresponding to stage 2 or higher chronic kidney disease [12] . The prognostic significance of these data with regard to evolution to end stage renal disease remains unknown. However, taken in the context of the protracted predicted lifespan, the cumulative burden of calcineurin inhibitor exposure, and the potential for future development of common medical comorbidities such as hypertension and diabetes, the high prevalence of significant renal impairment bodes raises serious concerns for the well being and longevity of pediatric liver transplant recipients [12] .
Cardiovascular risk profile: hypertension, diabetes, and hyperlipidemia
Current immunosuppressive medications are well known to predispose to potent atherosclerosis risk factors including hypertension, diabetes, and hyperlipidemia. In general, their impact on pediatric liver transplant recipients appears less than on their adult counterparts. However, there is serious concern that the cumulative impact over time for affected patients bodes poorly. Avitzur et al. reported that eight of 32 patients (25%) required antihypertensive treatment, a rate consistent with several previous reports [7, 9, 13] . Moreover, it has been suggested that hypertension may be substantially underdiagnosed. Del Compare et al. [14] compared office blood pressure measurements with 24-h ambulatory blood pressure monitoring in stable pediatric recipients 1.1-11.5 years (median 5.1 years) after liver transplantation who had good renal function and who were not on any antihypertensive medications. Out of 61 eligible patients, 32 were excluded: 18 (30%) because of chronic renal insufficiency (calculated GFR < 80 ml/min), 12 (20%) because of recent changes in immunosuppression, and two because of declined consent. Out of the 29 stable patients with good renal function who were studied, eight (28%) met criteria for hypertension by ambulatory blood pressure monitoring whereas only one was patient of hypertension based on office blood pressure measurements. With regard to other metabolic diagnoses, approximately 6% of all 10-year pediatric liver transplant survivors are patients of diabetes [9] . Although 26% had elevated fasting cholesterol and 45% had elevated triglycerides, none was prescribed lipid-lowering agents. Again, though these metabolic abnormalities were often mild and affected a modest proportion of patients, the potential for cumulative morbidity particularly over the anticipated long life of a pediatric transplant recipient span merits concern.
Malignancy Pediatric liver recipients are particularly susceptible to the malignancy classically related to immunosuppression, PTLD, a condition that is almost always associated with Epstein-Barr virus (EBV). The most common pediatric liver diseases necessitate transplantation during the infant or toddler years [3] , earlier than the usual timeframe of primary EBV infection. Because primary infection is a much more potent risk factor than reactivation infection, EBV seronegative compared with seropositive recipients are five to seven times more likely to develop clinically important EBV infection and PTLD [15, 16] . PTLD has been a leading cause of death beyond the immediate postoperative period [17] .
The other malignancy widely acknowledged as a direct sequela of immunosuppression is skin cancer. The risks of squamous cell carcinoma and melanoma are increased by 65 and 3.4 times higher, respectively, in renal and cardiac transplant recipients compared with the general population [18] . Specific information on pediatric transplant recipients suggests that skin cancers typically do not occur until the second decade after transplantation, at an average age of 26-28 years [19] . As in adults, but even more so, there was reversal of the squamous cell to basal cell carcinoma ratio compared with the general population. Spread to lymph nodes was also more common in pediatric recipients than in adult recipients.
Immunosuppression practices in the early posttransplant period
The recent emergence of more and more data detailing the prevalence and morbidity of complications associated with immunosuppression has engendered increasing interest to reduce the implicit burden of lifelong immunosuppression for pediatric liver transplant recipients. Minimization of immunosuppression early after transplantation may offer the greatest theoretical advantage.
However, as the early posttransplant period is widely accepted as the time of highest rejection risk ( Fig. 3) , aggressive reduction of early maintenance immunosuppression is not readily possible. In actuality, early posttransplant immunosuppression has intensified during the last decade. There has been increasing use of induction immunosuppression, dominated by interleukin-2 receptor antibodies [21] . Currently, approximately 26% of pediatric liver transplant recipients receive induction, compared to the nadir of 5% in 1997. For maintenance immunosuppression, calcineurin inhibitors remain the primary agent, given to greater than 90% of recipients at hospital discharge from transplantation. However, cyclosporine has essentially been replaced by its more potent cousin, tacrolimus [20, 21] . Similarly, the vast majority of the children treated with an antiproliferative agent are administered mycophenolate mofetil, considered to be a more potent agent that azathioprine [20] . These trends of intensified early posttransplant immunosuppression have facilitated decreased use of corticosteroids. Although complete avoidance remains uncommon, there are clear trends that corticosteroids are increasingly discontinued during the first or second posttransplant year [20] .
An approach that has been explored in adult transplantation to enable substantial reduction of maintenance immunosuppression early after transplantation is administration of a potent induction regimen. Typically, a strongly depletional drug such as rabbit thymoglobulin or alemtuzamab has been given for induction, followed by monotherapy with tacrolimus [22] [23] [24] [25] [26] [27] . This strategy has not, however, been embraced by the pediatric liver transplantation community out of concern that the shortterm and long-term consequences of such potent drugs on the immune system of infants and toddlers, the predominant liver transplant population, are poorly defined.
Immunosuppression practices late after transplantation
It is well known that incidence of acute rejection drops substantially as time passes after liver transplantation (Fig. 3) . Data from the SPLIT registry clearly show that immunosuppression exposure decreases in parallel [20] . Corticosteroids and antiproliferative agents are frequently discontinued during the first posttransplant year. By 12 and 18 months after transplantation, approximately one-third and one-half of all pediatric transplant recipients are receiving only a single immunosuppressant, respectively. Calcineurin inhibitors in general and tacrolimus in specific are the primary agents used for maintenance immunosuppression. Doses of calcineurin inhibitors also decrease steadily. Particularly, if the dose is normalized to recipient weight or trough levels are considered, it is clear that calcineurin inhibitor exposure diminishes over time. Nevertheless, even as much as 6 years after transplantation, mean trough cyclosporine and tacrolimus levels center around 100 and 6 ng/ml, respectively. Therefore, though immunosuppression exposure does indeed diminish, it is still substantial particularly considering the long lifetimes of pediatric liver transplant recipients.
Immunosuppression withdrawal experiences in pediatric liver transplant recipients
Of all solid organs that are transplanted, the liver has historically been regarded as being immunologically privileged -the most resistant to immunologic attack and damage. Presentation of antigens through the portal venous system is more likely to result in a tolerizing response than presentation through the systemic venous system. In several allogeneic models ranging from rodent to canine to swine, minimal or even no exposure to immunosuppression has resulted in successful and durable graft function after transplantation [28] [29] [30] [31] . In the human arena, the liver is unique among transplanted solid organs in several ways. First, though episodes of acute rejection commonly connote deleterious outcomes for nearly all other transplanted organs, acute rejection after liver transplantation does not share in such longterm connotations [32, 33] . Second, it is well known that some episodes of acute rejection may resolve spontaneously without treatment [34, 35] . Third, though chronic rejection threatens the longevity of other transplanted organs, its incidence and importance is less in the post-liver transplant setting, particularly in the age of modern immunosuppression [36] . Furthermore, it has Immunosuppression withdrawal after pediatric liver transplantation Feng 509 been suggested that tacrolimus has nearly eliminated the threat of chronic rejection for pediatric liver transplant recipients in general [37, 38] and that living donor liver transplants may be particularly immune to chronic rejection [39] . And finally, though humoral mechanisms of acute and chronic allograft rejection are operational for all other solid organs, they exert little impact on liver allografts. All of these favorable immunologic factors, in conjunction with specter of lifelong immunosuppression with its attendant toxicities, have stimulated tremendous interest in complete immunosuppression withdrawal for pediatric liver transplant recipients.
As for clinical data, there exist single-center experiences that demonstrate successful, prospective immunosuppression withdrawal from liver transplant recipients [24, 27, [40] [41] [42] [43] [44] [45] [46] [47] [48] 49 ] . The collective experience has also been recently reviewed [50, 51 ] . Two, in particular, are informative regarding children. The University of Pittsburgh has reported on 95 prospectively withdrawn recipients; at study entry, 31 were at least 20 years old and the remaining were 21-68 years old [40, 41] . At last publication, 19% were completely off immunosuppression, 39% were still weaning, 29% had experienced rejection, and 13% have withdrawn from the study. Of the 28 patients with rejection, 18 had biopsy-proven episodes, seven had clinically suspected episodes, and three had biopsy findings suggestive of 'incipient' chronic rejection but not diagnostic of chronic rejection. All 28 recipients were treated with resumption or escalation of baseline immunosuppression, with or without bolus corticosteroids. More recently, outcomes regarding the pediatric cohort have been updated [51 ] . Out of 64 pediatric liver transplant recipients that have attempted immunosuppression withdrawal, 22 (34%) were successful, nine (14%) experienced acute rejection, whereas the remaining 33 (52%) have reached neither endpoint and are still weaning. Although it appears as if the pediatric cohort had better outcomes with higher weaning success rate and lower rejection rate, these conclusions are substantially tempered by the fact that large proportions of both cohorts were still weaning.
Kyoto University has also reported its experience with immunosuppression withdrawal in pediatric liver transplant recipients. Overall, they observed a success rate for complete immunosuppression withdrawal of 42% (48 out of 115 recipients) [43, 44] . Twenty patients (17%) experienced rejection; all rejection episodes were easily reversed except one that required OKT3 therapy. One recipient developed chronic rejection that was successfully treated with triple immunosuppression -corticosteroid, tacrolimus, and mycophenolate mofetil. A more recent update of this center's experience indicates that they have successfully weaned 87 pediatric liver trans-plants recipients [49 ] . As the report was primarily focused on immunologic studies, it provided no updated information as to how many recipients attempted weaning or experienced rejection or both.
Although these reports regarding immunosuppression withdrawal in adults and children prove that functional tolerance can occur in liver transplant recipients and create the general context of expectation as to its frequency, they have not yielded definitive data regarding the mechanism(s) of or biomarkers that may predict, characterize, or identify functional tolerance. Intriguing glimpses into the signature of functional tolerance have recently emerged that have yet to be prospectively validated. Two groups, one studying children and the other studying adults, have reported that functionally tolerant liver transplant recipients, compared with immunosuppression-dependent liver transplant recipients and healthy controls, have increased proportion and absolute numbers of circulating gd T cells [49 ,52 ] . Moreover, functionally tolerant patients show a predominance of Vgd1þ over Vgd2þ cells. One of the two groups has also suggested that the expression patterns of as few as 22 genes can accurately predict the outcome of withdrawal [52 ] . Currently, there is an ongoing clinical trial of immunosuppression withdrawal to prospectively test the combination of lymphocyte subsets and gene expression markers for accuracy to identify functionally tolerant adult liver transplant recipients (http://clinicaltrials.gov/ ct2/show/NCT00647283?term=immunosuppression+ AND+withdrawal&rank=9).
In the United States, out of the three trials funded by the Immune Tolerance Network/National Institute of Allergy and Infectious Diseases that are actively exploring immunosuppression withdrawal after liver transplantation, one specifically targets pediatric recipients of parental living donor transplants (http://clinicaltrials. gov/ct2/show/NCT00320606?term=immunosuppression+ AND+withdrawal&rank=1). The trial is small, aiming to enroll 20 stable recipients, at two centers, who will withdraw from immunosuppression over a minimum of 36 weeks. Although the primary endpoint is one of efficacy -the proportion of participants who are successfully withdrawn from immunosuppression, defined as those who remain off immunosuppression for at least 1 year -there is an overarching emphasis on clarifying the safety of tightly controlled drug withdrawal. An integral part of the study is the serial evaluation of peripheral blood and liver tissue over a 5-year period before, during, and after withdrawal to identify biomarkers of functional tolerance. If this pilot trial in children proves to be safe and, particularly, if a fingerprint of tolerance emerges from this or other withdrawal experiences or both, then the pediatric liver transplant community can look forward to future trials that will enroll a sufficient number of patients to answer critical questions regarding the medical, psychosocial, and immunologic efficacy of immunosuppression withdrawal.
Conclusion
As pediatric liver transplantation has matured into a highly successful endeavor in the past 10-15 years, attention has increasingly turned toward delineating the long-term challenges and concerns of and for this unique patient cohort. Only recently has any information emerged regarding the cumulative impact of immunosuppression on the health and well being of long-term survivors. These reports have stimulated interest in immunosuppression withdrawal. Although single-center experiences have provided proof of concept, efficacy with regard to the frequency of success, consequences of failure, and magnitude of future benefit remains to be elucidated by well conducted and adequately powered clinical trials.
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